Premium
3D cell culture systems – towards primary drug discovery platforms: An interview with Heinz Ruffner (Novartis) and Jan Lichtenberg (InSphero)
Author(s) -
Göbel Uta
Publication year - 2012
Publication title -
biotechnology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.144
H-Index - 84
eISSN - 1860-7314
pISSN - 1860-6768
DOI - 10.1002/biot.201200176
Subject(s) - drug discovery , chemistry , biochemistry
Advanced cell culture systems for regenerative medicine, drug efficacy and toxicity testing, enabling technologies to create and analyze 3D cell culture systems were the topics of the 3D cell culture meeting taking place in March 14–16, 2012 at the Technopark in Zurich, Switzerland. At this meeting Biotechnology Journal had the pleasure to talk to Dr. Heinz Ruffner , Novartis AG, and Dr. Jan Lichtenberg , co‐founder and CEO of InSphero AG, about challenges and perspectives in using 3D cell culture systems as primary drug discovery platforms.